Research programme: antisense glucagon receptor antagonists - Ionis
Latest Information Update: 04 Nov 2017
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 05 May 2006 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)